UCLA researchers find no evidence of association between iron levels and atherosclerosis risk

Published on December 18, 2013 at 1:00 AM · No Comments

"The surprise was that we found no evidence that iron excess exacerbates atherosclerosis or that hepcidin is influenced at all by atherosclerosis," said L-on Kautz, a postdoctoral fellow in Nemeth's laboratory and the study's first author. "However, it is important to keep in mind that this is a mouse model. We need to see whether the same is true in humans."

Other research groups have begun analyzing hepcidin in atherosclerosis patients, Nemeth noted. Among the additional questions raised by the study is whether significantly lowering iron below normal levels could have a positive atherosclerosis-related effect.

The study was funded by the National Institutes of Health. Nemeth is a cofounder of Intrinsic LifeSciences, a company developing hepcidin diagnostics, and a consultant for Xenon Pharma, a company developing iron-related therapeutics.

The research was a collaboration between Nemeth's lab and the lab of study author Jake Lusis, a professor of medicine and human genetics and of microbiology, immunology and molecular genetics at the David Geffen School of Medicine at UCLA.

Additional authors included Victoria Gabayan, Xuping Wang, Judy Wu, James Onwuzurike, Grace Jung and Dr. Bo Qiao, all of the UCLA Department of Medicine, and Dr. Tomas Ganz, of the UCLA Department of Pathology.

For more news, visit the UCLA Newsroom and follow us on Twitter.

Source: University of California - Los Angeles Health Sciences

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment